Targeting chronic myeloid leukemia stem cells

Kinstrie, R. and Copland, M. (2012) Targeting chronic myeloid leukemia stem cells. Current Hematologic Malignancy Reports, 8(1), pp. 14-21. (doi: 10.1007/s11899-012-0148-8) (PMID:23264204)

Full text not currently available from Enlighten.


Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder that is characterized by the presence of the fusion oncogene BCR-ABL that encodes the tyrosine kinase BCR-ABL. Constitutive expression of BCR-ABL leads to the unregulated production of mature myeloid cells in the bone marrow and their subsequent release into the blood. Untreated, CML will progress from a chronic to accelerated phase over a number of years before quickly proceeding to a terminal blast crisis phase, reminiscent of acute leukemia. The advent of tyrosine kinase inhibitors has led to much improved management of the disease, but these drugs do not provide a cure as they are unable to eradicate the most primitive, quiescent fraction of CML stem cells. This review looks at recent research into targeting CML stem cells and focuses on major signalling pathways of interest.

Item Type:Articles (Other)
Glasgow Author(s) Enlighten ID:Kinstrie, Dr Ross and Copland, Professor Mhairi
Authors: Kinstrie, R., and Copland, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Current Hematologic Malignancy Reports
ISSN (Online):1558-822X
Published Online:20 December 2012

University Staff: Request a correction | Enlighten Editors: Update this record